Treatment advance of (neo) adjuvant chemoradiation for the elderly intermediate and locally advanced rectal cancer patients

doi:10.3877/cma.j.issn.2095-3224.2016.01.05

Abstract

Abstract:

Rectal cancer is one of the most commonly diagnosed cancers in China and worldwide, with an increasing trend in the proportion of elderly patients. However, as the prospective evidence designed specifically for treating this population is sparse, and the treatment algorithms for these patients become controversial, it is clear that a significant percentage of elderly rectal cancer patients has been treated less than optimally. This paper provides overviews of the recent data on epidemiology, treatment modality, especially (neo) adjuvant chemoradiation in the treatment of older rectal cancer patients, and to discuss the optimal treatment algorithm for the intermediate and locally advanced rectal cancer in the elderly.

Key words: Rectal neoplasms, Therapy, Elderly

Wenyang Liu, Jing Jin. Treatment advance of (neo) adjuvant chemoradiation for the elderly intermediate and locally advanced rectal cancer patients[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(01): 21-26.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.01.05

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I01/21

References 42

[1]	Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. Journal of Clinical Oncology, 2015, 33(32): 3826-3833.
[2]	Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res, 2015, 27(1): 2-12.
[3]	Papamichael D, Audisio R, Horiot JC, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol, 2009, 20(1): 5-16.
[4]	Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol, 2005, 11(30): 4685-4688.
[5]	Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. Jama, 2004, 291(22): 2720-2726.
[6]	Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship Between Age at Diagnosis and Treatments. Journal of the American Geriatrics Society, 1985, 33(9): 585-589.
[7]	Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol, 2015, 26(2): 288-300.
[8]	Kunkler IH, Audisio R, Belkacemi Y, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol, 2014, 25(11): 2134-2146.
[9]	Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol, 2015, 26(3): 463-476.
[10]	Group, C. C. C. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet, 2000, 356(9234): 968-974.
[11]	Larsen SG, Wiig JN, Tretli S, et al.Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis, 2006, 8(3): 177-185.
[12]	Rutten HJ, den Dulk M, Lemmens VE, et al. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol, 2008, 9(5): 494-501.
[13]	Kiran RP, Attaluri V, Hammel J, et al. A novel nomogram accurately quantifies the risk of mortality in elderly patients undergoing colorectal surgery. Ann Surg, 2013, 257(5): 905-908.
[14]	Townsley C, Pond GR, Peloza B, et al.Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol, 2005. 23(16): 3802-3810.
[15]	Townsley C, Pond GR, Peloza B, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol, 2005, 55(3): 231-240.
[16]	Fiorica F, Cartei F, Licata A, et al.Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev, 2010, 36(7): 539-549.
[17]	Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med, 2006, 355(11): 1114-1123.
[18]	Gérard JP, Conroy T, Bonnetain F,et al.Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol, 2006, 24(28): 4620-4625.
[19]	Sauer R, Becker H, Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
[20]	Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol, 2012, 23(10): 2479-2516.
[21]	Sebag-Montefiore D, Stephens RJ, Steele R, et al.Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, 2009, 373(9666): 811-820.
[22]	Ngan SY, Burmeister B, Fisher RJ, et al.Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. Journal of Clinical Oncology, 2012, 30(31): 3827-3833.
[23]	Peeters KC, Marijnen CA, Nagtegaal ID,et al.The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Annals of surgery, 2007, 246(5): 693-701.
[24]	Tan E, Tilney H, Thompson M, et al.The United Kingdom National Bowel Cancer Project-epidemiology and surgical risk in the elderly. European Journal of Cancer, 2007, 43(15): 2285-2294.
[25]	Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol, 2002, 20(5): 1192-1202.
[26]	Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer, 1990, 66(1): 49-55.
[27]	Pignon T, Horiot JC, Bolla M, et al.Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol, 1997, 42(2): 107-120.
[28]	Shahir MA, Lemmens VE, van de Poll-Franse LV, et al.Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer, 2006, 42(17): 3015-3021.
[29]	Rutten H, den Dulk M, Lemmens V, et al. Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery. Eur J Cancer, 2007, 43(15): 2295-2300.
[30]	Maas HA, Lemmens VE, Nijhuis PH, et al. Benefits and drawbacks of short-course preoperative radiotherapy in rectal cancer patients aged 75 years and older. Eur J Surg Oncol, 2013, 39(10): 1087-1093.
[31]	Lorchel F, Peignaux K, Créhange G,et al.Preoperative radiotherapy in elderly patients with rectal cancer. Gastroenterol Clin Biol, 2007, 31(4): 436-441.
[32]	Pasetto LM, Friso ML, Pucciarelli S, et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res, 2006, 26(5B): 3913-3923.
[33]	Pettersson D, Holm T, Iversen H,et al.Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. British Journal of Surgery, 2012, 99(4): 577-583.
[34]	Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. British Journal of Surgery, 2010, 97(4): 580-587.
[35]	Pettersson D, Lörinc E, Holm T, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. British Journal of Surgery, 2015, 102(8): 972-978.
[36]	Ceelen W, Fierens K, Van Nieuwenhove Y, et al. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer, 2009, 124(12): 2966-2972.
[37]	Neugut AI, Fleischauer AT, Sundararajan V, et al.Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol, 2002, 20(11): 2643-2650.
[38]	Martijn H, Vulto JC.Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer, 2007, 43(15): 2301-2306.
[39]	Dobie SA, Warren JL, Matthews B, et al. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer, 200, 112(4): 789-799.
[40]	Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol, 2010, 28(10): 1638-1644.
[41]	François E, Azria D, Gourgou-Bourgade S, et al. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol, 2014, 110(1): 144-149.
[42]	Jiang DM, Raissouni S, Mercer J, et al. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. Annals of Oncology, 2015, 6(10): 2102-2106.

Please choose a citation manager

Content to export